 Tarun Garg
Concepts (160)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromans | 2 | 2024 | 62 | 1.110 |
Why?
| | Radiation-Protective Agents | 2 | 2024 | 116 | 1.040 |
Why?
| | Killer Cells, Natural | 5 | 2015 | 106 | 0.780 |
Why?
| | Prostaglandin D2 | 3 | 2005 | 27 | 0.740 |
Why?
| | Immunotherapy, Adoptive | 4 | 2015 | 134 | 0.680 |
Why?
| | Oxidative Stress | 4 | 2008 | 956 | 0.550 |
Why?
| | Pigment Epithelium of Eye | 2 | 2004 | 16 | 0.480 |
Why?
| | Immunologic Factors | 2 | 2005 | 130 | 0.450 |
Why?
| | T-Lymphocytes | 2 | 2012 | 374 | 0.440 |
Why?
| | Multiple Myeloma | 8 | 2022 | 3049 | 0.430 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2012 | 62 | 0.420 |
Why?
| | Vitamin E | 2 | 2024 | 107 | 0.410 |
Why?
| | Mitochondria | 3 | 2014 | 489 | 0.320 |
Why?
| | Osteolysis | 2 | 2022 | 87 | 0.310 |
Why?
| | Reactive Oxygen Species | 4 | 2014 | 491 | 0.300 |
Why?
| | Macaca mulatta | 2 | 2024 | 106 | 0.290 |
Why?
| | Methylmercury Compounds | 1 | 2005 | 13 | 0.270 |
Why?
| | Microglia | 1 | 2005 | 137 | 0.240 |
Why?
| | Tyrphostins | 1 | 2003 | 16 | 0.230 |
Why?
| | Insulins | 1 | 2023 | 1 | 0.230 |
Why?
| | Hair Diseases | 1 | 2023 | 9 | 0.230 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 170 | 0.210 |
Why?
| | Acute Radiation Syndrome | 1 | 2022 | 23 | 0.210 |
Why?
| | Bone Marrow | 1 | 2024 | 414 | 0.200 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 445 | 0.190 |
Why?
| | Insulin Resistance | 1 | 2023 | 299 | 0.180 |
Why?
| | Bone Resorption | 1 | 2022 | 328 | 0.180 |
Why?
| | Hydrogen Peroxide | 3 | 2005 | 142 | 0.180 |
Why?
| | Blotting, Western | 3 | 2015 | 684 | 0.170 |
Why?
| | Cell Proliferation | 2 | 2015 | 1097 | 0.170 |
Why?
| | Animals | 6 | 2024 | 14402 | 0.170 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 166 | 0.160 |
Why?
| | Boronic Acids | 2 | 2009 | 197 | 0.150 |
Why?
| | Pyrazines | 2 | 2009 | 203 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 472 | 0.150 |
Why?
| | Cell Survival | 4 | 2012 | 657 | 0.150 |
Why?
| | Interleukin-6 | 3 | 2023 | 315 | 0.130 |
Why?
| | Lymphocyte Activation | 2 | 2012 | 197 | 0.130 |
Why?
| | Membrane Potentials | 2 | 2005 | 139 | 0.130 |
Why?
| | Artemisinins | 1 | 2014 | 10 | 0.120 |
Why?
| | Flow Cytometry | 3 | 2012 | 547 | 0.120 |
Why?
| | Mice, SCID | 2 | 2012 | 196 | 0.120 |
Why?
| | Antimalarials | 1 | 2014 | 30 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 1060 | 0.120 |
Why?
| | Tumor Cells, Cultured | 2 | 2012 | 477 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 121 | 0.120 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 29 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2014 | 194 | 0.110 |
Why?
| | K562 Cells | 1 | 2012 | 47 | 0.110 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2012 | 10 | 0.110 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 11 | 0.110 |
Why?
| | Interleukin-2 | 1 | 2012 | 75 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 99 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2012 | 52 | 0.100 |
Why?
| | Receptors, KIR | 2 | 2008 | 15 | 0.100 |
Why?
| | Coculture Techniques | 1 | 2012 | 159 | 0.100 |
Why?
| | Apoptosis | 3 | 2014 | 1302 | 0.100 |
Why?
| | Cells, Cultured | 3 | 2004 | 1737 | 0.100 |
Why?
| | Azacitidine | 1 | 2010 | 37 | 0.100 |
Why?
| | Benzamides | 1 | 2010 | 54 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2010 | 72 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 56 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 1476 | 0.090 |
Why?
| | Humans | 15 | 2023 | 54304 | 0.090 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 170 | 0.090 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2008 | 31 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 552 | 0.090 |
Why?
| | Mice | 3 | 2012 | 6428 | 0.090 |
Why?
| | Pyrimidines | 1 | 2010 | 196 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2023 | 1229 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2010 | 360 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2009 | 270 | 0.080 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 399 | 0.070 |
Why?
| | Cerebellum | 1 | 2008 | 142 | 0.070 |
Why?
| | Cell Membrane | 1 | 2007 | 279 | 0.070 |
Why?
| | Cell Line | 2 | 2008 | 1152 | 0.070 |
Why?
| | Down-Regulation | 1 | 2007 | 388 | 0.070 |
Why?
| | Aconitate Hydratase | 1 | 2005 | 14 | 0.070 |
Why?
| | Ethanol | 1 | 2008 | 323 | 0.070 |
Why?
| | Drug Interactions | 1 | 2005 | 206 | 0.060 |
Why?
| | Skin, Artificial | 1 | 2004 | 9 | 0.060 |
Why?
| | Transduction, Genetic | 1 | 2004 | 50 | 0.060 |
Why?
| | Genetic Engineering | 1 | 2004 | 27 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 75 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 564 | 0.060 |
Why?
| | Keratinocytes | 1 | 2004 | 96 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2005 | 634 | 0.060 |
Why?
| | Dependovirus | 1 | 2004 | 102 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2008 | 583 | 0.060 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2003 | 26 | 0.060 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| | Cystatin M | 1 | 2022 | 21 | 0.060 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 85 | 0.060 |
Why?
| | Aldehydes | 1 | 2003 | 97 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 132 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 101 | 0.050 |
Why?
| | Actins | 1 | 2003 | 132 | 0.050 |
Why?
| | Cell Death | 1 | 2003 | 223 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2022 | 63 | 0.050 |
Why?
| | C-Reactive Protein | 1 | 2023 | 159 | 0.050 |
Why?
| | Models, Biological | 1 | 2005 | 825 | 0.050 |
Why?
| | Arthritis, Reactive | 1 | 2001 | 2 | 0.050 |
Why?
| | RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| | Phosphorylation | 1 | 2003 | 613 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 435 | 0.050 |
Why?
| | Intestines | 1 | 2022 | 204 | 0.050 |
Why?
| | Risk Factors | 2 | 2023 | 3934 | 0.050 |
Why?
| | Amyloidosis | 1 | 2001 | 85 | 0.050 |
Why?
| | Blood Glucose | 1 | 2023 | 487 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2022 | 720 | 0.040 |
Why?
| | Cytokines | 1 | 2023 | 677 | 0.040 |
Why?
| | Osteoclasts | 1 | 2022 | 469 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2015 | 1090 | 0.040 |
Why?
| | Transcription Factors | 1 | 2003 | 622 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 314 | 0.040 |
Why?
| | Cell Culture Techniques | 2 | 2012 | 112 | 0.040 |
Why?
| | Time Factors | 1 | 2005 | 3207 | 0.040 |
Why?
| | Middle Aged | 4 | 2023 | 13076 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2022 | 1651 | 0.030 |
Why?
| | Female | 5 | 2015 | 28457 | 0.030 |
Why?
| | Recurrence | 2 | 2008 | 692 | 0.030 |
Why?
| | Adult | 3 | 2023 | 14189 | 0.030 |
Why?
| | Male | 5 | 2015 | 27335 | 0.030 |
Why?
| | 4-1BB Ligand | 1 | 2012 | 1 | 0.030 |
Why?
| | Gene Frequency | 1 | 2013 | 120 | 0.030 |
Why?
| | Young Adult | 1 | 2023 | 4313 | 0.030 |
Why?
| | Interleukin-15 | 1 | 2012 | 19 | 0.030 |
Why?
| | Blood Component Removal | 1 | 2012 | 18 | 0.030 |
Why?
| | Cryopreservation | 1 | 2012 | 31 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 309 | 0.030 |
Why?
| | Alleles | 1 | 2013 | 277 | 0.030 |
Why?
| | Genotype | 1 | 2013 | 600 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2015 | 645 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 89 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 15 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 76 | 0.020 |
Why?
| | Haplotypes | 1 | 2008 | 105 | 0.020 |
Why?
| | Ligands | 1 | 2008 | 229 | 0.020 |
Why?
| | Aged | 2 | 2015 | 10054 | 0.020 |
Why?
| | Matrix Metalloproteinases | 1 | 2008 | 52 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 240 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 485 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 131 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2007 | 111 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2008 | 396 | 0.020 |
Why?
| | DNA Methylation | 1 | 2010 | 575 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 868 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 1551 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 922 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2004 | 61 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2004 | 139 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1141 | 0.020 |
Why?
| | Genetic Therapy | 1 | 2004 | 121 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2008 | 1664 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 570 | 0.010 |
Why?
| | Rats | 1 | 2008 | 3417 | 0.010 |
Why?
| | Treatment Failure | 1 | 2001 | 141 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 142 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 5609 | 0.010 |
Why?
| | Adolescent | 1 | 2001 | 6896 | 0.010 |
Why?
|
|
Garg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|